ReviewIndian journal of hematology & blood transfusion : an official journal of Indian Society of Hematology and Blood Transfusion2026
Anti Thymocyte Globulin- Development.
Review in Indian journal of hematology & blood transfusion : an official journal of Indian Society of Hematology and Blood Transfusion, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Anti thymocyte globulin (ATG) is a polyclonal antibody primarily derived from rabbit, horse, or porcine sources, used to prevent or treat T-cell-mediated rejection, graft-versus-host disease (GVHD), and aplastic anaemia (AA). It has demonstrated efficacy in reducing both acute and chronic GVHD and improving graft survival in hematopoietic stem cell transplantation (HSCT) and solid organ transplant settings without affecting overall survival. Mechanistically, ATG depletes T-cells, modulates myeloid cells via PDL1 induction, and induces immune regulation. Rabbit ATG (rATG) is commonly used in organ transplants and HSCT. Horse or equine ATG (eATG) has proven efficacy in haematological disorders, particularly AA. Indigenous eATG (Thymogam) is widely used as part of immunosuppressive therapy (IST) in AA. Porcine ATG (pATG) is emerging as a therapeutic alternative in AA. Therapeutic drug monitoring (TDM) has potential to improve dosing precision and immune reconstitution. Future directions focus on optimizing dosing, personalization and expanding indications. Manufacturing of ATG is complex process and requires multilevel monitoring and quality control to ensure efficacy and safety of the products for human use. This article aims to summarise the developmental evolution, composition, mechanism of action, overview of clinical uses of ATG, dosing, administration, and monitoring strategies, including the role of TDM and a brief description of the manufacturing process and various quality aspects of ATGs for clinical use.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.